Efficacy and Safety of Carica Papaya Leaf Extract in Dengue Fever with Thromobocytopenia in Paediatric age Group

Micro Labs Limited0 个研究点目标入组 285 人开始时间: 待定最近更新: 2021年11月24日

试验速览

暂无简介。

•1.Subjects who are confirmed to have DF or DHF grade I and II by NS1 antigen test
•2.Subjects having thrombocytopenia with platelet count 30,000-1,00,000 /micro litre
•3.Subjects with a baseline alanine transaminase (ALT) level of not more than 3 times of the upper limit of the normal range (not more than 165 U/L)
•4.Subjects parent/ guardian who is willing to give informed consent to participate in study.

•1. Subjects with Dengue hemorrhagic fever grade III and IV
•2. Subjects with platelet count less than 30,000/micro litre
•3. Subjects who have received blood or blood products transfusion during the current illness
•4. Subjects with thrombocytopenia Purpura (ITP), Leukaemia, Haemophilia
•5. Subjects who have a serum ALT level 3 times higher than the upper limit of the normal range ( >165 U/L)
•6. Impaired renal function with serum creatinine >1.5 mg/dl(males) and >1.4 mg/dl(females)
•7. Participation in another trial with an investigational drug within 1 month prior to this trial.
•8. Hypersensitivity to any of the components of the formulation
•9. The presence of any other condition that leads the investigator to conclude that the patient is inappropriate for inclusion in this clinical study.

发起方